Stoke Therapeutics, Inc.
STOK
$9.76
-$0.12-1.22%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 362.08% | 1.30% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 362.08% | 1.30% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 362.08% | 1.30% | |||
| SG&A Expenses | 1.20% | -2.65% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.93% | 2.12% | |||
| Operating Income | 54.49% | -2.25% | |||
| Income Before Tax | 60.34% | -2.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 60.34% | -2.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 60.34% | -2.86% | |||
| EBIT | 54.49% | -2.25% | |||
| EBITDA | 55.45% | -2.32% | |||
| EPS Basic | 60.82% | -1.80% | |||
| Normalized Basic EPS | 60.81% | -1.81% | |||
| EPS Diluted | 60.82% | -1.80% | |||
| Normalized Diluted EPS | 60.81% | -1.81% | |||
| Average Basic Shares Outstanding | 1.22% | 1.03% | |||
| Average Diluted Shares Outstanding | 1.22% | 1.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||